{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:48:45Z","timestamp":1780469325163,"version":"3.54.1"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.critrevonc.2022.103847","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T03:05:17Z","timestamp":1665975917000},"page":"103847","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences"],"prefix":"10.1016","volume":"180","author":[{"given":"Irfan","family":"Cicin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Kawamura","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-We","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Smolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arif","family":"Abdillah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.critrevonc.2022.103847_bib1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.lungcan.2012.02.003","article-title":"ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis","volume":"76","author":"Ahn","year":"2012","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103847_bib2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s12032-014-0477-7","article-title":"Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib","volume":"32","author":"Ajimizu","year":"2015","journal-title":"Med Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103847_bib3","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3390\/cancers12040942","article-title":"Brigatinib and alectinib for ALK rearrangement-positive advanced non-small cell lung cancer with or without central nervous system metastasis: a systematic review and network meta-analysis","volume":"12","author":"Ando","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103847_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5334\/aogh.2419","article-title":"Global epidemiology of lung cancer","volume":"85","author":"Barta","year":"2019","journal-title":"Ann. Glob. Health"},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103847_bib5","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","article-title":"Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets","volume":"5","author":"Brastianos","year":"2015","journal-title":"Cancer Disco"},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103847_bib6","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2022.103847_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.lungcan.2018.03.008","article-title":"Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer","volume":"119","author":"Burudpakdee","year":"2018","journal-title":"Lung Cancer"},{"issue":"26","key":"10.1016\/j.critrevonc.2022.103847_bib8","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1200\/JCO.2017.77.5841","article-title":"Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials","volume":"36","author":"Camidge","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2022.103847_bib9","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"31","key":"10.1016\/j.critrevonc.2022.103847_bib10","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1200\/JCO.20.00505","article-title":"Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial","volume":"38","author":"Camidge","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103847_bib11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/13696998.2017.1302453","article-title":"The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib","volume":"20","author":"Carlson","year":"2017","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.critrevonc.2022.103847_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103400","article-title":"Treatment of brain metastases in ALK-positive non-small cell lung cancer","volume":"165","author":"Ceddia","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103847_bib13","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/cam4.1059","article-title":"A large, single-center, real-world study of clinicopathological characteristics and treatment in advanced ALK-positive non-small-cell lung cancer","volume":"6","author":"Chen","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.critrevonc.2022.103847_bib14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.wneu.2016.08.046","article-title":"Outcomes of gamma knife radiosurgery in combination with crizotinib for patients with brain metastasis from non-small cell lung cancer","volume":"95","author":"Choi","year":"2016","journal-title":"World Neurosurg."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103847_bib15","doi-asserted-by":"crossref","first-page":"CNS28","DOI":"10.2217\/cns-2018-0007","article-title":"Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice","volume":"8","author":"Chukwueke","year":"2019","journal-title":"CNS Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2022.103847_bib16","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.4161\/cbt.22255","article-title":"Isolated central nervous system progression on crizotinib: an achilles heel of non-small cell lung cancer with EML4-ALK translocation?","volume":"13","author":"Chun","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.critrevonc.2022.103847_bib17","unstructured":"clinica, Aado, 2020-2021, Recommendaciones de tratamiento oncologico."},{"issue":"17","key":"10.1016\/j.critrevonc.2022.103847_bib18","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1200\/JCO.2014.59.0539","article-title":"Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases","volume":"33","author":"Costa","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103847_bib19","first-page":"2866","article-title":"Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results From ASCEND-2","volume":"34","author":"Crin\u00f2","year":"2016"},{"key":"10.1016\/j.critrevonc.2022.103847_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.3369","article-title":"Inserting ensartinib into the starting lineup for ALK-rearranged lung cancer-a likely limited role on a deep bench","author":"Dagogo-Jack","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2022.103847_bib21","article-title":"Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse","volume":"6","author":"Dagogo-Jack","year":"2022","journal-title":"JCO Precis Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103847_bib22","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/03007995.2018.1533458","article-title":"Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients","volume":"35","author":"Davies","year":"2019","journal-title":"Curr. Med Res Opin."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103847_bib23","article-title":"Clinical observation of crizotinib in the treatment of ALK-positive advanced non-small cell lung cancer","volume":"215","author":"Deng","year":"2019","journal-title":"Pathol. Res Pr."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103847_bib24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12885-016-3017-3","article-title":"The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases","volume":"17","author":"Deng","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2022.103847_bib25","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jocn.2015.05.068","article-title":"Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy","volume":"26","author":"Dudnik","year":"2016","journal-title":"J. Clin. Neurosci."},{"issue":"13","key":"10.1016\/j.critrevonc.2022.103847_bib26","doi-asserted-by":"crossref","first-page":"21903","DOI":"10.18632\/oncotarget.15746","article-title":"Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study","volume":"8","author":"Duruisseaux","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103847_bib27","doi-asserted-by":"crossref","first-page":"807","DOI":"10.6004\/jnccn.2018.0062","article-title":"NCCN guidelines insights: non-small cell lung cancer, version 5.2018","volume":"16","author":"Ettinger","year":"2018","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103847_bib28","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.ejca.2014.02.001","article-title":"Prospective screening for ALK: clinical features and outcome according to ALK status","volume":"50","author":"Fallet","year":"2014","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103847_bib29","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/annonc\/mdy405","article-title":"Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study","volume":"29","author":"Gadgeel","year":"2018","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103847_bib30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/bjc.2017.395","article-title":"Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC","volume":"118","author":"Gadgeel","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103847_bib31","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(14)70362-6","article-title":"Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1\/2 study","volume":"15","author":"Gadgeel","year":"2014","journal-title":"Lancet Oncol."},{"issue":"34","key":"10.1016\/j.critrevonc.2022.103847_bib32","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2016.68.4639","article-title":"Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cance","volume":"34","author":"Gadgeel","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103847_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-227299","article-title":"Rapid regression of neurological symptoms in patients with metastasised ALK+ lung cancer who are treated with lorlatinib: a report of two cases","volume":"12","author":"Gafer","year":"2019","journal-title":"BMJ Case Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103847_bib34","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jtho.2015.10.010","article-title":"Alectinib dose escalation reinduces central nervous system responses in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer relapsing on standard dose alectinib","volume":"11","author":"Gainor","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103847_bib35","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/JTO.0000000000000455","article-title":"Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib","volume":"10","author":"Gainor","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103847_bib36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2017.05.019","article-title":"Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria","volume":"82","author":"Gandhi","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103847_bib37","first-page":"71","article-title":"First-line treatment of advanced ALK-positive non-small-cell lung cancer","volume":"6","author":"Gandhi","year":"2015","journal-title":"Lung Cancer (Auckl. )"},{"key":"10.1016\/j.critrevonc.2022.103847_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2019.04.013","article-title":"Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis","volume":"133","author":"Gaye","year":"2019","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103847_bib39","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S1470-2045(16)30392-8","article-title":"Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: A single-arm, open-label, phase 1\/2 trial","volume":"17","author":"Gettinger","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103847_bib40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: Proposals for revision of the TNM Stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103847_bib41","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1185\/03007995.2015.1057115","article-title":"Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy","volume":"31","author":"Gu\u00e9rin","year":"2015","journal-title":"Curr. Med Res Opin."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103847_bib42","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3111\/13696998.2014.1003644","article-title":"Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden","volume":"18","author":"Gu\u00e9rin","year":"2015","journal-title":"J. Med Econ."},{"issue":"10089","key":"10.1016\/j.critrevonc.2022.103847_bib43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103847_bib44","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/jjco\/hyx045","article-title":"Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset","volume":"47","author":"Hida","year":"2017","journal-title":"Jpn J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103847_bib45","unstructured":"Horn, L., Wang, Z., Wu, G., Poddubskaya, E., Mok, T., Reck, M., Wakelee, H., Chiappori, A., Lee, D., Breder, V., Orlov, S., Cicin, I., Cheng, Y., Liu, Y., Fan, Y., Zhou, J., Oertel, V., Mao, L., Selvaggi, G., Wu, Y., 2020, Phase 3 randomized study of ensartinib vs crizotinib in anaplastic lymphoma kinase (ALK)\u2013positive NSCLC patients: eXalt3, Proceedings of the WCLC 2020 Virtual Presidential Symposium. Online."},{"key":"10.1016\/j.critrevonc.2022.103847_bib46","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial","author":"Horn","year":"2021","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103847_bib47","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4103\/ijc.IJC_186_17","article-title":"Ceritinib in anaplastic lymphoma kinase-positive nonsmall cell lung cancer among patients who were previously exposed to crizotinib: experience from the Indian subcontinent","volume":"54","author":"Joshi","year":"2017","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103847_bib48","first-page":"452","article-title":"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial","volume":"17","author":"Kim","year":"2016"},{"key":"10.1016\/j.critrevonc.2022.103847_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-200867","article-title":"Long-lasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer","volume":"2013","author":"Kinoshita","year":"2013","journal-title":"BMJ Case Rep."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103847_bib50","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/jjco\/hyy016","article-title":"Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset","volume":"48","author":"Kiura","year":"2018","journal-title":"Jpn J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103847_bib51","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1148\/radiol.2018180648","article-title":"Validity of RECIST version 1.1 for response assessment in metastatic cancer: a prospective, multireader study","volume":"290","author":"Kuhl","year":"2019","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103847_bib52","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0360-3016(98)00442-8","article-title":"Identification of prognostic factors in patients with brain metastases: a review of 1292 patients","volume":"43","author":"Lagerwaard","year":"1999","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103847_bib53","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cllc.2018.12.020","article-title":"Efficacy and safety of lorlatinib in Korean non-small-cell lung cancer patients with ALK or ROS1 rearrangement whose disease failed to respond to a previous tyrosine kinase inhibitor","volume":"20","author":"Lee","year":"2019","journal-title":"Clin. Lung Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103847_bib54","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/03007995.2018.1541443","article-title":"Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls","volume":"35","author":"Li","year":"2019","journal-title":"Curr. Med Res Opin."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103847_bib55","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1080\/13696998.2020.1762620","article-title":"Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors","volume":"23","author":"Lin","year":"2020","journal-title":"J. Med Econ."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103847_bib56","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jtho.2018.12.002","article-title":"Efficacy of alectinib in patients with ALK-positive NSCLC and symptomatic or large CNS metastases","volume":"14","author":"Lin","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103847_bib57","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1159\/000486862","article-title":"Real-world treatment patterns, survival, and prediction of CNS progression in ALK-positive non-small-cell lung cancer patients treated with first-line crizotinib in Latin America oncology practices","volume":"94","author":"Mart\u00edn","year":"2018","journal-title":"Oncology"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103847_bib58","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/cas.13977","article-title":"Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan","volume":"110","author":"Masuda","year":"2019","journal-title":"Cancer Sci."},{"issue":"13","key":"10.1016\/j.critrevonc.2022.103847_bib59","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1200\/JCO.2003.12.122","article-title":"Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases","volume":"21","author":"Mehta","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103847_bib60","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11060-016-2184-z","article-title":"Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series","volume":"129","author":"Metro","year":"2016","journal-title":"J. Neurooncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103847_bib61","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2004.05.128","article-title":"Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial","volume":"22","author":"Meyers","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103847_bib62","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.critrevonc.2022.103847_bib63","unstructured":"National Comprehensive Cancer Network, Non-small cell lung cancer (Version 6.2021). Accessed September 30, 2021."},{"key":"10.1016\/j.critrevonc.2022.103847_bib64","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.lungcan.2018.04.015","article-title":"Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"121","author":"Nishio","year":"2018","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103847_bib65","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","article-title":"Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study","volume":"29","author":"Novello","year":"2018","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103847_bib66","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1200\/JCO.2015.63.9443","article-title":"Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study","volume":"34","author":"Ou","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103847_bib67","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fonc.2014.00248","article-title":"The management of brain metastases in non-small cell lung cancer","volume":"4","author":"Owen","year":"2014","journal-title":"Front Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103847_bib68","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrclinonc.2014.25","article-title":"Current approaches to the treatment of metastatic brain tumours","volume":"11","author":"Owonikoko","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103847_bib69","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jtho.2018.12.014","article-title":"Natural history and factors associated with overall survival in Stage IV ALK-rearranged non-small cell lung cancer","volume":"14","author":"Pacheco","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103847_bib70","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jtho.2018.07.001","article-title":"The incidence of brain metastases in Stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib","volume":"13","author":"Patil","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103847_bib71","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2022.103847_bib72","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103847_bib73","doi-asserted-by":"crossref","first-page":"389","DOI":"10.6004\/jnccn.2013.0054","article-title":"A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib","volume":"11","author":"Riess","year":"2013","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103847_bib74","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1023\/A:1006308808769","article-title":"Diagnostic accuracy of MRI compared to CCT in patients with brain metastases","volume":"44","author":"Schellinger","year":"1999","journal-title":"J. Neurooncol"},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103847_bib75","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3390\/cancers10070224","article-title":"Current molecular-targeted therapies in NSCLC and their mechanism of resistance","volume":"10","author":"Schrank","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103847_bib76","first-page":"e41","article-title":"Phase III randomized study of ensartinib vs crizotinib in anaplastic lymphoma kinase (ALK) positive NSCLC patients: eXalt3. J Thoracic","volume":"15","author":"Selvaggi","year":"2020","journal-title":"Oncol"},{"issue":"21","key":"10.1016\/j.critrevonc.2022.103847_bib77","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103847_bib78","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103847_bib79","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103847_bib80","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol."},{"issue":"10072","key":"10.1016\/j.critrevonc.2022.103847_bib81","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103847_bib82","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamaoncol.2016.3834","article-title":"Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA)","volume":"3","author":"Sperduto","year":"2017","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103847_bib83","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jtho.2020.09.018","article-title":"Preliminary clinical and molecular analysis results from a single-arm phase 2 trial of brigatinib in patients with disease progression after next-generation ALK tyrosine kinase inhibitors in advanced ALK+ NSCLC","volume":"16","author":"Stinchcombe","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103847_bib84","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41571-019-0320-3","article-title":"Current approaches to the management of brain metastases","volume":"17","author":"Suh","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103847_bib85","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103847_bib86","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/JTO.0b013e31828c28e7","article-title":"Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement","volume":"8","author":"Takeda","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2022.103847_bib87","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1200\/JCO.2016.70.5749","article-title":"Three-year follow-up of an alectinib phase I\/II study in ALK-positive non-small-cell lung cancer: AF-001JP","volume":"35","author":"Tamura","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103847_bib88","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jtho.2021.08.009","article-title":"Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation","volume":"17","author":"Thomas","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103847_bib89","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2217\/pgs.13.236","article-title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small-cell lung cancer","volume":"15","author":"Tibaldi","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.critrevonc.2022.103847_bib90","first-page":"CD003869","article-title":"Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases","volume":"4","author":"Tsao","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103847_bib91","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/thoraxjnl-2012-202297","article-title":"Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004\u20132007","volume":"68","author":"Walters","year":"2013","journal-title":"Thorax"},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103847_bib92","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1159\/000502755","article-title":"Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer","volume":"42","author":"Wang","year":"2019","journal-title":"Oncol. Res Treat."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103847_bib93","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/annonc\/mdy554","article-title":"Pan-Asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS","volume":"30","author":"Wu","year":"2019","journal-title":"Ann. Oncol."},{"issue":"51","key":"10.1016\/j.critrevonc.2022.103847_bib94","doi-asserted-by":"crossref","first-page":"84666","DOI":"10.18632\/oncotarget.13179","article-title":"Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases","volume":"7","author":"Xing","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103847_bib95","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11523-019-00637-5","article-title":"Efficacy of crizotinib for advanced ALK-rearranged non-small-cell lung cancer patients with brain metastasis: a multicenter, retrospective study in China","volume":"14","author":"Xing","year":"2019","journal-title":"Target Oncol."},{"key":"10.1016\/j.critrevonc.2022.103847_bib96","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.lungcan.2016.04.006","article-title":"Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer","volume":"97","author":"Yoshida","year":"2016","journal-title":"Lung Cancer"},{"issue":"22","key":"10.1016\/j.critrevonc.2022.103847_bib97","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-16-0569","article-title":"The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK Inhibitors in preclinical models","volume":"22","author":"Zhang","year":"2016","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103847_bib98","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.21037\/jtd.2019.03.76","article-title":"Anaplastic lymphoma kinase inhibitors in non-small cell lung cancer patients with brain metastases: a meta-analysis","volume":"11","author":"Zhang","year":"2019","journal-title":"J. Thorac. Dis."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103847_bib99","doi-asserted-by":"crossref","first-page":"e631","DOI":"10.1016\/j.cllc.2019.06.013","article-title":"Management of central nervous system metastases in patients with advanced anaplastic lymphoma kinase-rearranged non-small-cell lung cancer during crizotinib treatment","volume":"20","author":"Zhao","year":"2019","journal-title":"Clin. Lung Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103847_bib100","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S2213-2600(19)30053-0","article-title":"Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.","volume":"7","author":"Zhou","year":"2019","journal-title":"Lancet Respir. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103847_bib101","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12885-017-3720-8","article-title":"Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment","volume":"18","author":"Zhou","year":"2018","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103847_bib102","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1111\/cas.14177","article-title":"Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer","volume":"110","author":"Zhou","year":"2019","journal-title":"Cancer Sci."},{"issue":"45","key":"10.1016\/j.critrevonc.2022.103847_bib103","article-title":"Crizotinib resistance overcome by ceritinib in an ALK-positive non-small cell lung cancer patient with brain metastases: a case report","volume":"96","author":"Zhu","year":"2017","journal-title":"Med. (Baltim. )"},{"issue":"26","key":"10.1016\/j.critrevonc.2022.103847_bib104","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1200\/JCO.2018.78.8554","article-title":"Infiltrating the blood-brain barrier in ALK-positive lung cancer","volume":"36","author":"Zweig","year":"2018","journal-title":"J. Clin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822002712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822002712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:49:41Z","timestamp":1760903381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842822002712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":104,"alternative-id":["S1040842822002712"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103847","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103847","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103847"}}